Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBFB | Q13951 | 4/20 | 0.56 |
| ▸ | CACNA1H | O95180 | 6/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.44 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.40 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.39 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4193032 | 0.99 | CBFB (0.55) | CBFBCACNA1HTRPV1CACNA1GCACNA1C | |
| SCHEMBL904608 | 0.92 | CBFB (0.67) | CBFBTRPV1NPBWR1NPC1MAPK1 | |
| SCHEMBL4179849 | 0.91 | TRPV1 (0.53) | CBFBCACNA1HTRPV1CACNA1GCACNA1C | |
| SCHEMBL4182134 | 0.89 | CBFB (0.55) | CBFBTRPV1NPBWR1NPC1MAPK1 | |
| SCHEMBL4189155 | 0.89 | CBFB (0.53) | CBFBCACNA1HTRPV1CACNA1GCACNA1C | |
| SCHEMBL4193029 | 0.88 | CBFB (0.51) | CBFBCACNA1HTRPV1CACNA1GCACNA1C | |
| SCHEMBL4191057 | 0.88 | CBFB (0.65) | CBFBTRPV1 | |
| SCHEMBL4186864 | 0.88 | CBFB (0.53) | CBFBCACNA1HCACNA1GCACNA1CCACNA1B | |
| SCHEMBL4189178 | 0.88 | CBFB (0.50) | CBFBCACNA1HCACNA1GCACNA1CCACNA1B | |
| SCHEMBL5166377 | 0.87 | CBFB (0.49) | CBFBCACNA1HTRPV1CACNA1GCACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2621915-B1 | NOVEL METHOD OF PREPARING BENZOIMIDAZOLE DERIVATIVES | DAE WOONG PHARMA (KR) | 2016-04-20 | — | — | EP | claimed |
| US-9199965-B2 | Benzoimidazole derivatives and pharmaceutical composition comprising the same | DAEWOONG CO., LTD. (KR) | 2015-12-01 | — | — | US | claimed |
| US-9040572-B2 | Method of preparing benzoimidazole derivatives | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2015-05-26 | — | — | US | claimed |
| EP-1861387-B1 | BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | DAE WOONG PHARMA (KR) | 2014-04-16 | — | — | EP | claimed |
| US-20090018124-A1 | Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2009-01-15 | — | — | US | claimed |
| EP-2621915-B1 | NOVEL METHOD OF PREPARING BENZOIMIDAZOLE DERIVATIVES | DAE WOONG PHARMA (KR) | 2016-04-20 | — | — | EP | disclosed |
| EP-2621915-B1 | NOVEL METHOD OF PREPARING BENZOIMIDAZOLE DERIVATIVES | DAE WOONG PHARMA (KR) | 2016-04-20 | — | — | EP | disclosed |
| US-9199965-B2 | Benzoimidazole derivatives and pharmaceutical composition comprising the same | DAEWOONG CO., LTD. (KR) | 2015-12-01 | — | — | US | disclosed |
| US-9199965-B2 | Benzoimidazole derivatives and pharmaceutical composition comprising the same | DAEWOONG CO., LTD. (KR) | 2015-12-01 | — | — | US | disclosed |
| US-9199965-B2 | Benzoimidazole derivatives and pharmaceutical composition comprising the same | DAEWOONG CO., LTD. (KR) | 2015-12-01 | — | — | US | disclosed |
| US-9040572-B2 | Method of preparing benzoimidazole derivatives | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2015-05-26 | — | — | US | disclosed |
| US-9040572-B2 | Method of preparing benzoimidazole derivatives | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2015-05-26 | — | — | US | disclosed |
| US-20130231477-A1 | NOVEL METHOD OF PREPARING BENZOIMIDAZOLE DERIVATIVES | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2013-09-05 | — | — | US | disclosed |
| US-20130231477-A1 | NOVEL METHOD OF PREPARING BENZOIMIDAZOLE DERIVATIVES | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2013-09-05 | — | — | US | disclosed |
| EP-2621915-A2 | NOVEL METHOD OF PREPARING BENZOIMIDAZOLE DERIVATIVES | Daewoong Pharmaceutical Co., Ltd (KR) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012044043-A2 | NOVEL METHOD OF PREPARING BENZOIMIDAZOLE DERIVATIVES | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012044043-A2 | NOVEL METHOD OF PREPARING BENZOIMIDAZOLE DERIVATIVES | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2012-04-05 | — | — | WO | disclosed |
| US-20090018124-A1 | Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2009-01-15 | — | — | US | disclosed |
| US-20090018124-A1 | Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2009-01-15 | — | — | US | disclosed |
| US-20090018124-A1 | Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018124-A1 | Novel Benzoimidazole Derivatives and Pharmaceutical Composition Comprising the Same | TRPV1, TRPA1, BDKRB2 | CBFB 1891/4885CACNA1H 522/4885TRPV1 1/4885 |
| US-20130231477-A1 | NOVEL METHOD OF PREPARING BENZOIMIDAZOLE DERIVATIVES | BRD1, BRD4, VAT1 | CBFB 3959/4885CACNA1H 369/4885TRPV1 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.